Our products

Reaching more than 130 countries
Our product portfolio is sold in over 130 countries on 5 continents.
Select the therapeutic area

Select consultation area *(mandatory)

Acecnou

Fosfomycin trometamol

Genitourinary System
With prescription

Actimag

Magnesium pidolate

Digestive and metabolic system
With prescription

Activa

Levonorgestrel, ethinylestradiol

Genitourinary System
With prescription

Cisterex

Imidafenacin

Genitourinary System
With prescription

Activa 21

Levonorgestrel, ethinylestradiol

Genitourinary System
With prescription

Activa 21 Soft

Levonorgestrel, ethinylestradiol

Genitourinary System
With prescription

Acyphina

Esomeprazole Magnesium Trihydrate

Digestive and metabolic system
With prescription

Alerbix

Bilastine

Dermatology
Respiratory System
With prescription

Alektos

Bilastine

Dermatology
Respiratory System
With prescription

Alergical Crema

Betamethasone, Fluocinolone

Dermatology
With prescription

Aligrin

Bilastine

Dermatology
Respiratory System
With prescription

Allertine

Bilastine

Dermatology
Respiratory System

Analgilasa

Caffeine, Codeine phosphate, Paracetamol

Central Nervous System
With prescription

Analgiplus

Paracetamol, Codeine phosphate

Central Nervous System
With prescription

Aquamed Active


Personal care and Hygiene
Pharmacovigilance

Have you noticed a side effect?

We are here to help you and continue our research to improve our solutions and the quality of our medicines.


News

Economic and Financial News
July 24th, 2025

Faes Farma increases revenue by 12.3% to €307.4 million

The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]

Economic and Financial News
July 16th, 2025

Faes Farma’s Shareholders’ Meeting approves the acquisition of 100% of SIFI

Shareholder support consolidates the transaction as a transformational step for the company’s strategy The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the […]

Economic and Financial News
June 25th, 2025

Faes Farma reaffirms its ambition and strategic plan to 2030 to its shareholders

The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%. All items […]

Economic and Financial News
June 10th, 2025

Faes Farma Acquires SIFI: A Transformational Step Aligned With 2030 Ambitions and Strategy

This acquisition consolidates Faes Farma as a leader in ophthalmology, incorporating a broad portfolio in this key therapeutic area. It enhances the Group’s international expansion, facilitating direct entry into new European markets. […]

Economic and Financial News
March 25th, 2025

Faes Farma signs an agreement to acquire Laboratorios Edol, a leader in ophthalmology in Portugal

Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth. This milestone reinforces Faes Farma’s international growth strategy and consolidates its position in […]